IL297240A - Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof - Google Patents
Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereofInfo
- Publication number
- IL297240A IL297240A IL297240A IL29724022A IL297240A IL 297240 A IL297240 A IL 297240A IL 297240 A IL297240 A IL 297240A IL 29724022 A IL29724022 A IL 29724022A IL 297240 A IL297240 A IL 297240A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- lazertinib
- tablet
- mesylate
- pharmaceutical formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063009623P | 2020-04-14 | 2020-04-14 | |
| US202063014277P | 2020-04-23 | 2020-04-23 | |
| PCT/IB2021/053035 WO2021209893A1 (en) | 2020-04-14 | 2021-04-13 | Pharmaceutical composition for oral administration comprising amin op yrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL297240A true IL297240A (en) | 2022-12-01 |
Family
ID=75562794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL297240A IL297240A (en) | 2020-04-14 | 2021-04-13 | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof |
Country Status (13)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| EP4349835A4 (en) * | 2021-06-01 | 2025-06-25 | Hangzhou Solipharma Co., Ltd. | Hydrated crystal form of lazertinib methanesulfonate, process for its preparation and use thereof |
| WO2023138492A1 (zh) * | 2022-01-19 | 2023-07-27 | 南京明德新药研发有限公司 | 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用 |
| CA3228195A1 (en) | 2023-05-23 | 2025-06-30 | Janssen Biotech, Inc. | Methods for treatment of non-small cell lung cancer (nsclc) |
| IL326946A (en) | 2023-09-05 | 2026-05-01 | Janssen Biotech Inc | Methods of treating non-small cell lung cancer |
| WO2026042017A1 (en) | 2024-08-19 | 2026-02-26 | Janssen Biotech, Inc. | Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc) |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6437006B1 (en) * | 1999-09-27 | 2002-08-20 | American Cyanamid Company | Pharmaceutical carrier formulation |
| US6399591B1 (en) | 2000-01-19 | 2002-06-04 | Yung-Shin Pharmaceutical Ind. Co., Ltd. | Chargeable pharmaceutical tablets |
| DE602007011792D1 (de) * | 2006-10-27 | 2011-02-17 | Fmc Corp | Gemeinsam aufbereitete mikrokristalline cellulose und zuckeralkohol als hilfsstoff für tablettenformulierungen |
| EP2198857A1 (en) * | 2008-12-19 | 2010-06-23 | Ratiopharm GmbH | Oral dispersible tablet |
| ES2713330T3 (es) | 2009-12-11 | 2019-05-21 | Sumitomo Dainippon Pharma Co Ltd | Comprimido recubierto en seco que se desintegra oralmente |
| ES2900353T3 (es) | 2010-04-07 | 2022-03-16 | Vertex Pharma | Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas |
| KR102373193B1 (ko) | 2012-11-21 | 2022-03-10 | 얀센 바이오테크 인코포레이티드 | 이중특이성 EGFR/c-Met 항체 |
| US20160151380A1 (en) * | 2013-07-12 | 2016-06-02 | The Regents Of The University Of California | Therapies for diseases caused by arthropod-borne parasites |
| MY179355A (en) | 2013-12-12 | 2020-11-05 | Almirall Sa | Pharmaceutical compositions comprising dimethyl fumarate |
| GB201402070D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| EP3929190B1 (en) | 2014-10-13 | 2024-12-25 | Yuhan Corporation | Compounds and compositions for modulating egfr mutant kinase activities |
| IL261998B2 (en) * | 2016-04-07 | 2023-03-01 | Chemocentryx Inc | Reducing your burden by giving ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors |
| UA126970C2 (uk) * | 2017-01-20 | 2023-03-01 | Екселіксіс, Інк. | Комбінації кабозантинібу і атезолізумабу для лікування раку |
| JP2020510027A (ja) * | 2017-03-08 | 2020-04-02 | アリアド ファーマシューティカルズ，インコーポレーテッド | ５−クロロ−ｎ４−［２−（ジメチルホスホリル）フェニル］−ｎ２−｛２−メトキシ−４−［４−（４−メチルピペラジン−１−イル）ピペリジン−１−イル］フェニル｝ピリミジン−２，４−ジアミンを含む医薬製剤 |
| AR111469A1 (es) * | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| DK3658547T3 (da) | 2017-07-28 | 2023-10-16 | Yuhan Corp | Fremgangsmåde til fremstilling af n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamid |
| RS63497B1 (sr) | 2017-07-28 | 2022-09-30 | Yuhan Corp | Intermedijeri korisni za sintezu derivata aminopirimidina, proces za pripremu istih i proces za pripremu derivata aminopirimidina korišćenjem istih |
| ES2962961T3 (es) | 2017-07-28 | 2024-03-22 | Yuhan Corp | Procedimiento de preparación de n-(5-((4-(4-(dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamida haciendo reaccionar la amina correspondiente con un cloruro de 3-halo-propionilo |
| CN110580014B (zh) * | 2018-06-11 | 2021-03-30 | 北京京东尚科信息技术有限公司 | 用于控制自动导引运输车的方法、装置和系统 |
| US12350734B2 (en) | 2018-07-20 | 2025-07-08 | Imerys Usa, Inc. | Recovering sand, bentonite and organics from foundry sand waste |
| KR20200043618A (ko) | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| CA3136632A1 (en) | 2019-04-11 | 2020-10-15 | Goldfinch Bio, Inc. | Spray-dried formulation of a pyridazinone trpc5 inhibitor |
| CN113784704A (zh) | 2019-04-17 | 2021-12-10 | 诺狄更斯公司 | 快速崩解大麻素片剂 |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| MX2022001159A (es) | 2019-07-31 | 2022-02-22 | Hoffmann La Roche | Nueva formulacion farmaceutica. |
| TW202228689A (zh) * | 2020-10-09 | 2022-08-01 | 美商賽若凡斯生物製藥研發智財有限責任公司 | 泛ｊａｋ抑制劑的調配物 |
-
2021
- 2021-04-12 TW TW110113031A patent/TWI923583B/zh active
- 2021-04-13 IL IL297240A patent/IL297240A/en unknown
- 2021-04-13 CA CA3180184A patent/CA3180184A1/en active Pending
- 2021-04-13 MX MX2022012898A patent/MX2022012898A/es unknown
- 2021-04-13 UY UY0001039171A patent/UY39171A/es unknown
- 2021-04-13 KR KR1020227039484A patent/KR20230002656A/ko active Pending
- 2021-04-13 AU AU2021257662A patent/AU2021257662B2/en active Active
- 2021-04-13 US US17/228,753 patent/US12138351B2/en active Active
- 2021-04-13 EP EP21719733.4A patent/EP4135669A1/en active Pending
- 2021-04-13 JP JP2022562451A patent/JP7787824B2/ja active Active
- 2021-04-13 PH PH1/2022/552454A patent/PH12022552454A1/en unknown
- 2021-04-13 CN CN202180028642.0A patent/CN115484937A/zh active Pending
- 2021-04-13 WO PCT/IB2021/053035 patent/WO2021209893A1/en not_active Ceased
-
2024
- 2024-11-07 US US18/939,761 patent/US20250177311A1/en active Pending
-
2025
- 2025-05-09 AU AU2025203347A patent/AU2025203347A1/en active Pending
- 2025-08-22 JP JP2025138920A patent/JP2025179094A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202207940A (zh) | 2022-03-01 |
| JP2025179094A (ja) | 2025-12-09 |
| JP2023522634A (ja) | 2023-05-31 |
| UY39171A (es) | 2021-10-29 |
| BR112022020609A2 (pt) | 2022-11-29 |
| WO2021209893A1 (en) | 2021-10-21 |
| AU2021257662B2 (en) | 2025-06-12 |
| EP4135669A1 (en) | 2023-02-22 |
| TWI923583B (zh) | 2026-05-01 |
| CN115484937A (zh) | 2022-12-16 |
| US20250177311A1 (en) | 2025-06-05 |
| CA3180184A1 (en) | 2021-10-21 |
| MX2022012898A (es) | 2023-01-24 |
| US12138351B2 (en) | 2024-11-12 |
| KR20230002656A (ko) | 2023-01-05 |
| PH12022552454A1 (en) | 2024-02-05 |
| AU2025203347A1 (en) | 2025-05-29 |
| US20210322323A1 (en) | 2021-10-21 |
| WO2021209893A8 (en) | 2022-10-13 |
| AU2021257662A1 (en) | 2022-12-15 |
| JP7787824B2 (ja) | 2025-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12138351B2 (en) | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof | |
| IL282163B1 (en) | A pharmaceutical preparation for oral administration containing an aminopyrimidine derivative or a salt thereof | |
| NZ583269A (en) | Novel forms of cddo methyl ester also known as methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28 oate | |
| KR100498765B1 (ko) | 서방성 제제 | |
| IL305435A (en) | Psilocybin compositions, methods of making and methods of using the same | |
| IL296014A (en) | Tablets containing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
| IL261745B2 (en) | Granular formulation of 5-methyl-1-phenyl-2(h1)-pyridone and method for its preparation | |
| IL296352A (en) | Method for treatment of covid-19-associated conditions | |
| IL293821A (en) | Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide | |
| TWI921305B (zh) | Rbp4抑制劑之調配物及使用方法 | |
| NO333892B1 (no) | Farmasøytiske sammensetninger som innbefatter kolloid silikondioksid | |
| IL259493A (en) | Solid dispersions containing sgc actuator | |
| IL224189A (en) | C-met modulator pharmaceutical compositions | |
| IL303352B1 (en) | Immediate-release tablets containing a drug and processes for forming the tablets | |
| IL294959A (en) | Methods of treatment for alpha-1 antitrypsin deficiency | |
| IL297642A (en) | Methods for using t-type calcium channel modulators | |
| IL297840A (en) | Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators | |
| IL298872A (en) | Dosage forms of eclobrutinib maleate | |
| IL322310A (en) | Methods for treating multiple sclerosis complex | |
| EA048109B1 (ru) | Фармацевтическая композиция для перорального введения, содержащая производное аминопиримидина или его фармацевтически приемлемую соль, гидрат или сольват | |
| BR112022020609B1 (pt) | Composição e formulação farmacêutica para administração oral que compreende derivado de aminopirimidina ou sal, hidrato ou solvato farmaceuticamente aceitável do mesmo e seus usos | |
| HK40085907A (en) | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof | |
| US20240216352A1 (en) | Lpa1 antagonists for treating interstitial lung disease | |
| HK40105586A (en) | Pharmaceutical composition comprising enavogliflozin | |
| IL295992A (en) | Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine |